Clinical Trial Search

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants

Primary: Survival at 1 Year After Transplantation — 10; 6 participants

Primary: 3 Years Event-free Survival — 51; 56; 126; 123 Participants

Primary: Overall Response (OR) Rate — 0.07 Proportion of participants

Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) — 3; 1; 0; 0 Participants

Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability

Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 26 participants

Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants

Primary: Progression-free Survival (PFS) at 2 Years — 69 percentage of participants

Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 21; 8 participants

Primary: Number of Participants With Response (Complete Response or Progressive Disease) — 2; 6 Participants

Primary: Overall Survival at 1 Year — 90 percentage of participants

Primary: Progression-free Survival at 2 Years — 76; 80 percentage of participants — p=0.11

Primary: Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC) — 67.8; 70.0; 68.1 percentage…

Primary: Clinical Response Rate — 1; 7; 0; 8 Participants

Primary: Progression-free Survival — 89 percentage of participants

Primary: Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response — 437; 238 Participants

Primary: Number of Participants With the Indicated Grade 4 Hematology Toxicities Following Iodine-131 Anti-B1 Antibody — 1; 1; 1; 1 participants

Primary: Objective Response Rate — 18.8; 33.3; 30.0 Percentage of Patients

Primary: Progression-Free Survival (PFS) — 73 percentage of participants

Primary: Proportion of Confirmed Tumor Response (Complete Response [CR], Unconfirmed CR, and Partial Response) — 0.48 proportion of participants

Primary: Progression Free Survival — 389; 334 days — p=0.039

Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0 Participants

Primary: Number of Patients With Objective Response — 10; 8 participants

Primary: Event-free Survival (EFS) Per Blinded Independent Review Committee (BIRC) Assessment — 3.0; 3.0 months — p== 0.694